Skip to content

18-012 - Clinical Trial to Learn if the Usual Chemotherapy, given before Surgery (Neoadjuvant Therapy) for Breast Cancer plus an Experimental Drug, is Better than the Usual Chemotherapy plus a Placebo

Status: open

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Treatment for Breast Cancer

Contact Us

Description

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. IRB Number 18-012

Sponsors

This trial is sponsored by NSABP.

Providers Associated With This Trial

Principle Investigator

This link will open in a new tab or window.